

21st Century Oncology

Radiation Therapy Services, Inc.

December 1st, 2006

MS16
K-8

Mrs. Sandy Gabriel
Senior Health Physicist
U.S. Nuclear Regulatory Commission, Region I
475 Allendale Road
King of Prussia, PA 19406-1415

03037177

RE: Mail Control No.: 139593
Radioactive Material License # 09-31141-01

Dear Mrs. Gabriel:

In response to your email dated November 09, 2006, requesting more information regarding the amendment to our referenced License, please let me inform you the following:

1. At the present time we would like to include Dr. Rafael Yankelevich as an Authorized Medical Physicist. Please find enclosed copy of NRC License # 37-01421 and a Letter from Geissenger Health System granting Dr. Yankelevich the status of Authorized Medical Physicist for HDR Brachytherapy.

2. Please find enclosed a letter form Dr. Constantine A. Mantz in which is described the clinical cases performed by Dr. Youssef under his supervision. Find also enclosed a copy of the outline of the Nucletron training performed by Dr. Youssef, and a copy of State of Florida Radioactive Materials License in which Dr. Mantz is listed as an Authorized User.

Should you have any questions or require more information, please feel free to contact me at 239-768-7377.

Sincerely,

Daniel H. Galmarini
Director of Physics and RSO

139593

NMSS/RGN1 MATERIALS-002

NRC FORM 374 (7-94) U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 6 PAGES

MATERIALS LICENSE

Amendment No. 46

CORRECTED COPY

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Geisinger Medical Center	In accordance with the letter dated January 15, 1997, 3. License Number 37-01421-01 is amended in its entirety to read as follows:
2. 100 North Academy Avenue Danville, Pennsylvania 17822-2408	4. Expiration Date July 31, 2000
	5. Docket or Reference No. 030-02984<37-19448-01 37-01421-05 37-27998-01

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material with Atomic Numbers 3 through 83 and half-life less than 120 days	A. Any	A. 500 millicuries of each radionuclide with a total possession limit of 5 curies
B. Any byproduct material with Atomic Numbers 3 through 83	B. Sealed sources	B. 6 curies of each radionuclide with a total possession limit of 12 curies
C. Carbon 14	C. Any	C. 200 millicuries
D. Calcium 45	D. Any	D. 60 millicuries
E. Hydrogen 3	E. Any	E. 5 curies
F. Phosphorus 32	F. Any	F. 700 millicuries
G. Sulfur 35	G. Any	G. 700 millicuries
H. Molybdenum 99	H. Any	H. 5 curies
I. Technetium 99m	I. Any	I. 7 curies
J. Iodine 131	J. Any	J. 3 curies
K. Iodine 125	K. Any	K. 300 millicuries
L. Cesium 137	L. Sealed sources (Isomedix Model ISO-1000)	L. 720 curies
M. Iridium 192	M. Sealed sources (Byk Mallinckrodt Model CIL BV)	M. 2 sources, one source not to exceed 10 curies and one source not to exceed 12 curies
N. Cesium 137	N. Sealed source (Amersham Model 77302)	N. 200 millicuries
O. Americium 241	O. Sealed source (Siemens Model 1074 LX)	O. 2 millicuries

9. Authorized use

A. through K. Medical diagnosis, therapy, and research in humans in accordance with any

NRC Form 374A (5-04) U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 5 PAGES

License number 37-01421-01

Docket or Reference number 030-02984 ~~37-01421-05~~ <37-19448-01 ~~37-27998-01~~

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

Amendment No. 46

applicable Food and Drug Administration (FDA) requirements. Research and development as defined in 10 CFR 30.4, including instrument calibration and student instruction.

L. For use in an AECL Gammacell 1000 Model A irradiator for the irradiation of material except explosives, flammables, or corrosives.

M. For use in a Nucletron Corporation MicroSelectron HDR remote afterloading brachytherapy unit for interstitial, intraluminal and intracavitary radiotherapy in humans. The source activity may not exceed 10 curies at the time of installation. One source in its shipping container for source replacement.

N. and O. For instrument calibrations.

CONDITIONS

10. Licensed material may be used only at the licensee's facilities located at 100 North Academy Avenue, Danville, Pennsylvania and 1000 East Mountain Drive, Wilkes-Barre, Pennsylvania.

11. A. Licensed material shall be used by, or under the supervision of, individuals designated in writing by the Radiation Safety Committee, Mildred Fleetwood, Ph.D. Chairperson.

B. The use of licensed material in or on humans shall be by a physician, dentist, or podiatrist as defined in 10 CFR 35.2.

C. Physicians, dentists, or podiatrists designated to use licensed material in or on humans shall meet the training criteria established in 10 CFR 35, Subpart J and shall be designated in writing by the licensee's Radiation Safety Committee.

D. Individuals designated to act as medical physicists for the high dose rate remote afterloading unit shall meet the training criteria specified in 10 CFR 35.961 and shall be designated in writing by the licensee's Radiation Safety Committee.

E. The Radiation Safety Officer for this license is Catherine M. Anderko.

12. Notwithstanding the requirements of 10 CFR 35.49(a) and (b), 35.100, 35.200, 35.300, 35.400 and 35.500 the licensee may use for any medical use any byproduct material or reagent kit. The licensee shall possess and use byproduct material for medical use in accordance with the prescriptive and performance criteria in the other sections of 10 CFR 35. This does not relieve the licensee from complying with applicable U.S. Food and Drug Administration (FDA) and other Federal and State requirements.

13. The licensee shall conduct a physical inventory every three months to account for all sealed sources and devices containing licensed material received and possessed pursuant to 10 CFR 35.59, 35.400 and 35.500 and every six months for all other sealed sources and devices.

14. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

15. A. Sealed sources and detector cells containing licensed material shall be tested for leakage and/or contamination at intervals not to exceed six months or at such other intervals as are specified by the certificate of registration referred to

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

PAGE 5 OF 6 PAGES	
License number	37-01421-01
Docket or Reference number	~~37-01421-05~~ 030-02984<37-19448-01 ~~37-27998-01~~
	Amendment No. 46

in 10 CFR 32.210, not to exceed three years.

B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed three months.

C. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.

E. Sealed sources and detector cells need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transfer to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

F. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source or detector cell shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within five days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety Branch, 475 Allendale Road, King of Prussia, Pennsylvania 19406. The report shall specify the source or detector cell involved, the test results, and corrective action taken.

G. The licensee is authorized to collect leak test samples for analysis by the licensee. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

16. The licensee shall possess and use byproduct material for human research in accordance with the prescriptive and performance criteria in all sections of 10 CFR Part 35 except sections 35.49(a) and (b), 35.100, 35.200, and 35.300.

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 OF 6 PAGES

License number 37-01421-01

Docket or Reference number ~~37-01421-05~~ 030-02984 <37-19448-01 ~~37-27998-01~~

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

Amendment No. 46

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

18. The licensee shall not acquire licensed material in a sealed source or device unless the source or device has been registered with the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or equivalent regulations of an Agreement State.

19. The licensee is authorized to hold radioactive material with a physical half-life of less than 120 days for decay-in-storage before disposal in ordinary trash, provided:

A. Waste to be disposed of in this manner shall be held for decay a minimum of ten half-lives.

B. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. A record of each such disposal permitted under this License Condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

20. A. Access to the treatment room housing each high dose rate remote afterloading brachytherapy unit shall be controlled by a door at each entrance.

B. Each entrance to the treatment room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

C. Electrical interlocks on each entrance door to the treatment room shall be tested for proper operation at least once each day of use.

D. In the event of malfunction of the door interlock, the unit shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

21. Prior to initiation of a treatment program, and subsequent to each source exchange for each high dose rate remote afterloading brachytherapy unit, a radiation survey shall be made of:

A. The source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the surface of the main source safe shall

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

PAGE 5 OF 6 PAGES

License number 37-01421-01

Docket or Reference number ~~37-01421-05~~ 030-02984<37-19448-01 ~~37-27998-01~~

Amendment No. 46

MATERIALS LICENSE
SUPPLEMENTARY SHEET

CORRECTED COPY

not exceed 2 millirem per hour.

B. All areas adjacent to the treatment room with the source in the exposed position. The survey shall clearly establish:

(1) That radiation doses to occupationally exposed individuals do not exceed the limits specified in 10 CFR 20.1201(a), 20.1207 and 20.1208.

(2) That radiation doses to individual members of the public do not exceed the limits specified in 10 CFR 20.1301(a).

22. The following shall be performed only by persons specifically authorized by the Commission or an Agreement State to perform such service:

A. Installation, and replacement of the sealed sources contained in each high dose rate remote afterloading brachytherapy unit.

B. Maintenance or repair operations on any high dose rate remote afterloading brachytherapy unit and associated equipment involving work on the source safe, the source driving unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.

23. In lieu of the source inventory described in 10 CFR 35.406, the licensee shall:

A. Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each high dose remote brachytherapy procedure.

B. Promptly make a survey of the area of use to confirm that no sources have been misplaced.

C. Make a record of the survey including survey instrument used, dose rate, time, date and name of the individual making the survey.

D. Retain the record of the survey in lieu of the record required in 10 CFR 35.406(d).

24. In lieu of 10 CFR 35.404(a), immediately after retracting the source from the patient into its shielded position in the remote afterloading device, radiation survey shall be made of the patient and the remote afterloading device with a portable radiation detection survey instrument to confirm that the source has been removed from the patient. Records of the survey shall be maintained in lieu of the record required in 10 CFR 35.404(b).

25. The licensee shall not perform repairs or alterations of the irradiator authorized in in item 9.L. involving removal of shielding or access to the licensed material. Removal, replacement, and disposal of sealed sources in the irradiator shall be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

26. The procedures contained in the manufacturer's instruction manual for the irradiator authorized by this license in item 9.L. shall be followed and a copy of this manual

NRC Form 374A (5-84) U.S. NUCLEAR REGULATORY COMMISSION

PAGE 6 OF 6 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 37-01421-01
~~37-01421-05~~
Docket or Reference number 030-02984<37-19448-01
~~37-27998-01~~

CORRECTED COPY

Amendment No. 46

shall be made available to each person using or having responsibility for the use of the device.

27. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated January 15, 1997 except Quality Management Program
B. Letter dated January 28, 1997
C. Letter dated July 11, 1997
D. Letter dated August 19, 1997
E. Letter dated October 16, 1997



For the U.S. Nuclear Regulatory Commission

Date NOV 18 1997

By _____
Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406

Geisinger
Health System

Permit for Use of Ionizing Radiation
Therapy Physicist

PERMIT # 99115
Amended on 2/12/01

Expiration Date: February 28, 2005

NRC License # 37-01421-01

Rafael Yankelevich, PhD.
is hereby granted the status "Authorized Medical Therapy Physicist" for the procedures listed below:

NRC Code Ref.	PA DEP Ref.	Description
35.400	224.301	Brachytherapy
		HDR Brachytherapy
	228	Linear Accelerator
35.400		Intravascular HDR Brachytherapy (IVB)

This permit is issued based on information submitted to the Medical Health Physics Office and is subject to the terms and conditions of the application materials and associated documents. The Geisinger Radiation Safety Committee reserves the right to withdraw this permit prior to the stated expiration date.

Mildred Fleetwood, PhD.
Chair, Radiation Safety Committee
Geisinger Health System

Catherine M. Anderko, M.S.
Senior Health Physicist, Radiation Safety Officer
Geisinger Health System

21st Century Oncology
Radiation Therapy Services, Inc.

December 1st, 2006

Sandy Gabriel
Senior Health Physicist
U.S. Nuclear Regulatory Commission, Region I
475 Allendale Road
King of Prussia, PA 19406-1415

RE: Mail Control No.: 139593
Radioactive Material License # 09-31141-01

Dear Mrs. Gabriel:

This is to inform that on October 11, 2006, Dr. Ashraf Youssef, M.D. has performed 5 HDR Brachytherapy cases under my supervision in our facility located at 7341 Gladiolus Drive, Fort Myers, FL under State of Florida Radioactive Materials License # 476-2 in which I am listed as an Authorized User.
I confirm that Dr. Youssef has satisfactorily completed the requirements in 10 CFR 35.960(b)(1), (b)(2), and (c) and has achieved a level of competency sufficient to function independently as an HDR authorized user.

Should you have any questions, please feel free to contact me at 239-768-7377.

Sincerely,

C. Mantz

Constantine A. Mantz, M.D.

Nucletron Corp. 2006

Physician mHDR Afterloader Training

A prerequisite for physicians attending this course is a complete understanding of the basics of Brachytherapy. The basics of Brachytherapy will not be taught. Treatment planning system knowledge is a plus.

Advance scheduling with Nucletron Training Department is required. Please call: 443-545-2210. Course date and time will be confirmed in writing upon receipt of participant registration. In event of an emergency, Nucletron reserves the right to cancel the course.

Course Goals

1. Increase understanding of the mHDR afterloading system
2. Promote discussion of the mHDR afterloading system
3. Presentation on applicators for bodysite solutions
4. Promote understanding of data output

Course Introduction

Instructor and student introductions
Overview of the program and training material

Topics Presented and Discussed

- Nucletron mHDR Afterloader
  - *Safety procedures*
  - mHDR Afterloader "do's and don'ts"
- Clinical Solutions
  - Use of Applicators
  - Types of Applicators
- Clinical Training mHDR Afterloader
- Physician's Guide to Treatment Planning
  - Overview of PLATO Treatment Planning System
  - Graphical Optimization
- Review of QA and discuss anatomy of accidents and misadministrations
- Hands on practice with the mHDR afterloader
- Evaluation module
  - Participants are required to complete the evaluation document

Certificate citing attendee's participation is issued at completion of course.

STATE OF FLORIDA
DEPARTMENT OF HEALTH
BUREAU OF RADIATION CONTROL

RADIOACTIVE MATERIALS LICENSE
SUPPLEMENTAL SHEET

21ST CENTURY ONCOLOGY, INC.
d/b/a Radiation Therapy Regional Center
12165 Metro Parkway, Suite 19B
Fort Myers, FL 33912

With reference to correspondence dated August 24, 2006 and September 8, 2006, State of Florida Radioactive Materials License Number 476-2 is hereby amended.

TO CHANGE CONDITION 12 AND 22 TO READ:

CONDITIONS

12. A. The following individuals are authorized for the materials and uses as indicated:

Authorized Material and Uses as Described in Items 6, 7, 8, and 9	Names
Iridium 192	Peter H. Blitzer, M.D. Daniel E. Dosoretz, M.D. Graciela R. Garton, M.D. Michael J. Katin, M.D. Bruce M. Nakfoor, Jr., M.D. Stephen J. Patrice, M.D. James H. Rubenstein, M.D. Larry N. Siiverman, M.D. David J. Rice, M.D. Constantine A. Mantz, M.D. Michael C. Hanus, M.D. Keith L. Miller, M.D. Chaundre Cross, M.D.

B. The radiation safety officer is Constantine A. Mantz, M.D.

C. Radiologic technologists who use and administer radioactive materials or perform brachytherapy or teletherapy procedures under the general supervision of an authorized user shall hold a valid certificate as required by Chapter 468, F.S.

STATE OF FLORIDA
DEPARTMENT OF HEALTH
BUREAU OF RADIATION CONTROL

RADIOACTIVE MATERIALS LICENSE
SUPPLEMENTAL SHEET

12. D. The authorized medical physicists for medical physics support are:

Authorized Material and Uses as Described in Items 6, 7, 8, and 9	Names
Iridium 192	Daniel H. Galmarini, M.S. Mark D. Leete, M.S. Carol Kestler, M.S. Eric Lee, M.S. Jeff White, M.S. Jung-Lung David Hung, M.S. Womah Neeranjun, M.S. Michael Soldano, Jr., M.S.

22. A. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, 8, and 9 of this license in accordance with statements, representations and procedures contained in the licensee's application dated November 26, 2004, signed by Daniel H. Galmarini, M.S., DABR, and correspondence dated:

November 16, 2004;
August 22, 2005 (New HDR);
July 10, 2006 (Disposition of RAM); and
August 24, 2006 (superficial treatments with the Nucletron Leipzig Application set), all signed by Daniel H. Galmarini, M.S., DABR.

STATE OF FLORIDA
DEPARTMENT OF HEALTH
BUREAU OF RADIATION CONTROL

RADIOACTIVE MATERIALS LICENSE
SUPPLEMENTAL SHEET

22. B. The licensee shall comply with all applicable requirements of Chapter 64E-5, Florida Administrative Code, and these regulations shall supersede the licensee's statements in applications or correspondence, unless the statements are more restrictive than the regulations.

For the Bureau of Radiation Control:

Issuance Date: OCT 18 2006

Jason M. Kelly
Environmental Specialist II
4052 Bald Cypress Way – Bin C21
Tallahassee, FL 32399-1741
(850) 245-4545

A party whose substantial interest is affected by this order may petition for an administrative hearing pursuant to sections 120.569 and 120.57, Florida Statutes. Such proceedings are governed by Rule 28-106, Florida Administrative Code. A petition for administrative hearing must be in writing and must be received by the Agency Clerk for the Department, within twenty-one (21) days from the receipt of this order. The address of the Agency Clerk is: Agency Clerk, 4052 Bald Cypress Way, BIN # A02, Tallahassee, Florida 32399-1703. The Agency Clerk's facsimile number is 850-410-1448. A copy of the petition should also be sent to: Bureau Chief, Bureau of Radiation Control, 4052 Bald Cypress Way, BIN # C21, Tallahassee, FL 32399-1741. The Bureau Chief's facsimile number is 850-487-0435. Mediation is not available as an alternative remedy. Your failure to submit a petition for hearing within 21 days from receipt of this order will constitute a waiver of your right to an administrative hearing, and this order shall become a "final order." Should this order become a final order, a party who is adversely affected by it is entitled to judicial review pursuant to Section 120.68, Florida Statutes. Review proceedings are governed by the Florida Rules of Appellate Procedure. Such proceedings may be commenced by filing one copy of a Notice of Appeal with the Agency Clerk of the Department of Health and a second copy, accompanied by the filing fees required by law, with the Court of Appeal in the appropriate District Court. The notice must be filed within 30 days of rendition of the final order.